882 related articles for article (PubMed ID: 9263331)
1. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
[TBL] [Abstract][Full Text] [Related]
2. Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Chem Biol Interact; 1998 Apr; 111-112():277-305. PubMed ID: 9679561
[TBL] [Abstract][Full Text] [Related]
3. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
5. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis.
Yokomizo A; Kohno K; Wada M; Ono M; Morrow CS; Cowan KH; Kuwano M
J Biol Chem; 1995 Aug; 270(33):19451-7. PubMed ID: 7642628
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs.
Thrall BD; Raha GA; Springer DL; Meadows GG
Pigment Cell Res; 1991 Dec; 4(5-6):234-9. PubMed ID: 1823927
[TBL] [Abstract][Full Text] [Related]
7. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells.
Benathan M; Alvero-Jackson H; Mooy AM; Scaletta C; Frenk E
Melanoma Res; 1992 Dec; 2(5-6):305-14. PubMed ID: 1337997
[TBL] [Abstract][Full Text] [Related]
8. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
[TBL] [Abstract][Full Text] [Related]
10. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
12. Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.
Ford JM; Hait WN; Matlin SA; Benz CC
Cancer Lett; 1991 Jan; 56(1):85-94. PubMed ID: 2004358
[TBL] [Abstract][Full Text] [Related]
13. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
14. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
15. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC
Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505
[TBL] [Abstract][Full Text] [Related]
16. Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells.
Chiu PY; Ko KM
Biofactors; 2006; 26(4):221-30. PubMed ID: 17119269
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Wu XX; Ogawa O; Kakehi Y
Int J Oncol; 2004 Jun; 24(6):1489-97. PubMed ID: 15138592
[TBL] [Abstract][Full Text] [Related]
18. Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance.
Armstrong DK; Gordon GB; Hilton J; Streeper RT; Colvin OM; Davidson NE
Cancer Res; 1992 Mar; 52(6):1416-21. PubMed ID: 1540950
[TBL] [Abstract][Full Text] [Related]
19. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
20. Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.
Vanhoefer U; Yin MB; Harstrick A; Seeber S; Rustum YM
Biochem Pharmacol; 1997 Mar; 53(6):801-9. PubMed ID: 9113101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
